Related references
Note: Only part of the references are listed.Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma
Juliette J. Hoefnagel et al.
MODERN PATHOLOGY (2006)
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma
J Iqbal et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma
X Sagaert et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients
K Kodama et al.
BLOOD (2005)
FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations
I Wlodarska et al.
LEUKEMIA (2005)
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis
M Berglund et al.
MODERN PATHOLOGY (2005)
The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma
P Brown et al.
JOURNAL OF MOLECULAR HISTOLOGY (2005)
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes
IS Lossos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome
SL Barrans et al.
BLOOD (2004)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
G Wright et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional Repressors
B Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
L Colomo et al.
BLOOD (2003)
Lymphoid malignancies: The dark side of B-cell differentiation
AL Shaffer et al.
NATURE REVIEWS IMMUNOLOGY (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
SL Barrans et al.
BLOOD (2002)
Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
RE Davis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer
SD Catz et al.
ONCOGENE (2001)
Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors
WG Shu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
